CD28 and type 2 diabetes mellitus: Despite no changes in the CD28 cell-surface molecule, the overall impact on cytokine profiles and glucose metabolism reinforces the potential of ω-3 fatty acids as a therapeutic strategy to mitigate inflammation in T2DM.